Long-term respiratory consequences of COVID-19 related pneumonia: a cohort study.
COVID-19
Coronavirus disease
Long-term sequelae
Pneumonia
Pulmonary fibrosis
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
11 Nov 2023
11 Nov 2023
Historique:
received:
21
04
2023
accepted:
31
08
2023
medline:
13
11
2023
pubmed:
12
11
2023
entrez:
11
11
2023
Statut:
epublish
Résumé
Our aims were to describe respiratory sequelae up to 12 months after discharge in COVID-19 patients with severe pneumonia requiring non-invasive respiratory support therapies. This study was undertaken at University Hospital Doctor Josep Trueta (Girona, Spain) between March 2020 and June 2020. Three months after discharge, we evaluated their dyspnoea and performed Saint George's respiratory questionnaire, pulmonary function tests, blood test, 6-min walking test, and a high-resolution CT (HRCT). At the six and 12-month follow-up, we repeated all tests except for pulmonary function, 6-min walking test, and HRCT, which were performed only if abnormal findings had been previously detected. Out of the 94 patients recruited, 73% were male, the median age was 62.9 years old, and most were non-smokers (58%). When comparing data three and 12 months after discharge, the percentage of patients presenting dyspnoea ≥ 2 decreased (19% vs 7%), the quality-of-life total score improved (22.8% vs 18.9%; p = 0.019), there were less abnormal results in the pulmonary function tests (47% vs 23%), the 6-min walking test distance was enhanced (368.3 m vs 390.7 m, p = 0.020), ground glass opacities findings waned (51.6% vs 11.5%), and traction bronchiectasis increased (5.6% vs 15.9%). Only age showed significant differences between patients with and without pulmonary fibrotic-like changes. Most patients improved their clinical condition, pulmonary function, exercise capacity and quality of life one year after discharge. Nonetheless, pulmonary fibrotic-like changes were observed during the follow-ups.
Sections du résumé
BACKGROUND
BACKGROUND
Our aims were to describe respiratory sequelae up to 12 months after discharge in COVID-19 patients with severe pneumonia requiring non-invasive respiratory support therapies.
METHODS
METHODS
This study was undertaken at University Hospital Doctor Josep Trueta (Girona, Spain) between March 2020 and June 2020. Three months after discharge, we evaluated their dyspnoea and performed Saint George's respiratory questionnaire, pulmonary function tests, blood test, 6-min walking test, and a high-resolution CT (HRCT). At the six and 12-month follow-up, we repeated all tests except for pulmonary function, 6-min walking test, and HRCT, which were performed only if abnormal findings had been previously detected.
RESULTS
RESULTS
Out of the 94 patients recruited, 73% were male, the median age was 62.9 years old, and most were non-smokers (58%). When comparing data three and 12 months after discharge, the percentage of patients presenting dyspnoea ≥ 2 decreased (19% vs 7%), the quality-of-life total score improved (22.8% vs 18.9%; p = 0.019), there were less abnormal results in the pulmonary function tests (47% vs 23%), the 6-min walking test distance was enhanced (368.3 m vs 390.7 m, p = 0.020), ground glass opacities findings waned (51.6% vs 11.5%), and traction bronchiectasis increased (5.6% vs 15.9%). Only age showed significant differences between patients with and without pulmonary fibrotic-like changes.
CONCLUSION
CONCLUSIONS
Most patients improved their clinical condition, pulmonary function, exercise capacity and quality of life one year after discharge. Nonetheless, pulmonary fibrotic-like changes were observed during the follow-ups.
Identifiants
pubmed: 37951891
doi: 10.1186/s12890-023-02627-w
pii: 10.1186/s12890-023-02627-w
pmc: PMC10638724
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
439Informations de copyright
© 2023. The Author(s).
Références
Chest. 2022 Mar;161(3):647-650
pubmed: 34582842
Respirology. 2022 Aug;27(8):605-616
pubmed: 35694728
Respir Med Case Rep. 2021;32:101359
pubmed: 33552895
Eur Respir J. 2022 Jul 13;60(1):
pubmed: 34949706
Eur Radiol. 2011 Nov;21(11):2244-54
pubmed: 21744289
Eur Respir J. 2021 Apr 29;57(4):
pubmed: 33419891
Lancet Respir Med. 2021 Jul;9(7):747-754
pubmed: 33964245
Respir Care. 2018 Jan;63(1):77-85
pubmed: 28874609
Ann Am Thorac Soc. 2021 May;18(5):799-806
pubmed: 33433263
Radiology. 2021 Nov;301(2):E396-E405
pubmed: 34313468
Eur Respir J. 2021 Apr 29;57(4):
pubmed: 33303540
EClinicalMedicine. 2020 Aug;25:100463
pubmed: 32838236
Respir Med. 1991 Sep;85 Suppl B:25-31; discussion 33-7
pubmed: 1759018
Eur J Radiol. 2020 Jul;128:109017
pubmed: 32387924
Radiology. 2021 Nov;301(2):E383-E395
pubmed: 34374591
Eur Respir J. 2014 Dec;44(6):1447-78
pubmed: 25359356
Lancet. 2022 Sep 3;400(10354):769-786
pubmed: 35964592
Radiology. 2021 Apr;299(1):E177-E186
pubmed: 33497317
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264